legaci product mileston drive aimovig shine
market close tuesday octob report third-quart
financi result total revenu billion versu estim billion
earn per share versu estim street estim
out-performance quarter driven legaci product notabl enbrel
sensipar corpor partner revenu million mileston payment
novarti nv repatha sale notic light million versu estim
million quarterli unit growth off-set price eros total quarterli
growth lastli compani repurchas million share second
quarter total billion leav addit billion remain current
author manag deploy opportunist summari report
result versu estim provid exhibit
return equiti ttm
one world lead biotechnolog compani special discoveri develop
commerci therapeut design treat unmet medic need primarili anemia inflamm
cardiovascular space compani key product includ epogen aranesp neulasta repatha
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
manag increas full year guidanc anticip revenu billion billion versu previou
guidanc billion billion high end revenu guidanc assum entranc gener sensipar
unit state year non-gaap ep guidanc also increas updat
guidanc revis estim outlin exhibit
addit product pipelin comment
launch aimovig impress million first full quarter launch line estim
million next two three quarter inform outlook aimovig given entranc
two competitor third quarter ensu formulari discuss pharmaci benefit manag addit
compani plan provid initi free trial cgrp antibodi may creat swing commerci patient next
quarter two
quarterli sale repatha impact signific price pressur despit unit growth appar
manag host investor call last week discuss decis lower list price repatha
new nation drug code ndc although assum discount repatha origin list price roughli next
year new ndc hope increas uptak class continu fall well short expect
recent launch humira biosimilar europ includ amgen amjevita octob provid new potenti
sourc revenu howev note first tender market agreement
agre upon discount brand exist price discount admittedli greater
previous anticip discount first year launch therefor reduc estim
sale amjevita
manag continu highlight compani bite program enter first car-t program
clinic collabor kite target small cell lung cancer look forward addit clinic data
bcma multipl myeloma aml upcom american societi hematolog
annual meet plan host investor event meet decemb discuss
compani bite platform strategi
guidanc previou new amgen report william blair compani estim exhibit inc guidanc estim dollar million except ep william blair
early-stag pipelin expand seven new therapi enter clinic third quarter includ
target car-t therapi small-cel lung cancer bispecif antibodi
sirna target lp collabor arrowhead outperform look forward
updat studi gain better understand commerci potenti
share close day valuat time revis ep estim given limit
revenu growth see come year see exhibit continu rate amgen share market perform
howev note continu acceler share repurchas favor tax chang signific cash balanc
like support current share price therefor see limit downsid
risk invest share includ limit increas competit reimburs threat
compani erythropoietin filgrastim franchis anticip increas biosimilar competit sever legaci
product come month creat total revenu headwind continu growth osteoporosi franchis
fda approv coheru biosimilar neulastaevenityeuropean regulatori decis postmenopaus osteoporosi kyprolisinclus data european regulatori label repathapotenti inclus repatha therapi physician treatment guidelin dec updat on-going phase trial patient acut myeloid leukemia dec updat on-going phase trial patient multipl eventinvestor event meet discuss compani bite platformimlygicphas result first line melanoma combin antibodi present phase ii data migrain biosimilar remicad regulatori trial infring case report exhibit bpsoper bpsnet report william blair estim inc growth tabl dollar million except ep william blair
prolia xgeva well uptak repatha aimovig essenti ensur maintain earn growth
regul commerci setback therefor dampen investor enthusiasm share activ clinic
regulatori calendar year underwhelm data regulatori delay and/or uncertainti could weigh heavili
dollar million except ep share million
corpor partner revenu royalti incom
cost expens
good sold
research develop
sell gener administr
total cost expens
incom oper
earn incom tax
provis incom tax
net incom attribut
 total revenu
sg total revenu
william blair affili seek busi compani cover research report result investor awar firm may conflict interest could affect object report
investor consid report singl factor make invest decis
sourc report william blair estim
